Product Specification Sheet

**Product Name:** VX-702  
**Catalog Number:** C8970

### Technical Information:
- **Chemical Formula:** C₁₉H₁₂F₄N₄O₂  
- **CAS #:** 479543-46-9  
- **Molecular Weight:** 404.32  
- **Purity:** > 98%  
- **Appearance:** White solid  
- **Solubility:** Soluble in DMSO up to 100 mM  
- **Chemical Name:** 1-(5-carbamoyl-6-(2,4-difluorophenyl)pyridin-2-yl)-1-(2,6-difluorophenyl)urea  
- **Storage:** Store solid powder at 4°C desiccated; Store DMSO solution at -20°C.  
- **Shelf Life:** In the unopened package, powder is stable for 1 year and DMSO solution is stable for 6 months under proper storage condition.

### Handling:
- To make 10 mM stock solution, add 0.247mL of DMSO for each mg of VX-702.  
- For DMSO solution, briefly spin the vial at 500 rpm in a 50 mL conical tube to ensure maximum sample recovery.

### Biological Activity:
VX-702 is an orally-available, aminopyridine-based, ATP-competitive inhibitor of p38 MAPK with a KD of 3.7 nM and 17 nM at 10 uM for p38a and p38b, respectively. [1] In an ex vivo blood assay primed with LPS<sub>5</sub> VX-702 dose-dependently inhibited the production of IL-6, IL-1b, TNFα at IC50 of 59, 122, and 99 ng/mL, respectively. [2] VX-702 was found to be equivalent to prednisolone and methotrexate in a mouse collagen-induced arthritis model.

Clinical efficacy models plus transient suppression of inflammation biomarkers suggest that p38 MAPK inhibition by agents such as VX-702 may not be a viable approach to the treatment of chronic inflammation in RA. [3]

### Reference:

For Technical Support: [technical@cellagentech.com](mailto:technical@cellagentech.com)

*Chemicals are sold for research use only, not for clinical or diagnostic use.*